TrialHuman vaccines & immunotherapeutics2025

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.

Ana Perroud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.